Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives

Bibliography

• ROSAMOND WD, CHAMBLESS LE, FOLSOM AR et al: Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl. J. Med. (1998) 339(13):861–867.
   PubMed Web of Science ®Google Scholar
• MURRAY CJ, LOPEZ AD: Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet (1997) 349(9063):1436–1442.
   PubMed Web of Science ®Google Scholar
• LEVINE GN, KEANEY JF JR VITA JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl. J. Med. (1995) 332(8):512–521.
   PubMed Web of Science ®Google Scholar
• CORESH J, KWITEROVICH PO JR: Small, dense low-density lipoprotein particles and coronary heart disease risk: a clear association with uncertain implications. "AMA (1996) 276(10:914–915.
   PubMedGoogle Scholar
• ORAM JF, YOKOYAMA S: Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. I Lipid Res. (1996) 37(12):2473–2491.
   PubMed Web of Science ®Google Scholar
• WILSON PW, D'AGOSTINO RB, LEVY D et al: Prediction of coronary heart disease using risk factor categories. Circulation (1998) 97(23):1837–1847.
   PubMedGoogle Scholar
• ENDO A, KURODA M, TSUJITA Y: ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. I Antibiot. (1976) 29(12):1346–1348.
   Google Scholar
• MABUCHI H, HABA T, TATAMI R et al: Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl. I Med. (1981) 305(9):478–482.
   PubMed Web of Science ®Google Scholar
• TOBERT JA: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev Drug Discov. (2003) 2(7):517–526.
   PubMed Web of Science ®Google Scholar
• GRUNDI SM, CLEAMAN JI, MERZ CN et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110:227–239.
   PubMed Web of Science ®Google Scholar
• ••Guidelines for the treatment ofdyslipidaemia.
   Google Scholar
• MARON DJ, FAZIO S, LINTON MF: Current perspectives on statins. Circulation (2000) 101(10:207–213.
   PubMedGoogle Scholar
• •A review on the pharmacology of statins.
   Google Scholar
• MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7–22.
   PubMed Web of Science ®Google Scholar
• BELLOSTA S, FERRI N, BERNINI F, PAOLETTI R, CORSINI A: Non-lipid-related effects of statins. Ann. Med. (2000) 32(3):164–176.
   PubMed Web of Science ®Google Scholar
• BOLEGO C, POLI A, CIGNARELLA A, CATAPANO AL, PAOLETTI R: Novel statins: pharmacological and clinical results. Cardiovasc. Drugs Ther. (2002) 16(3):251–257.
   PubMed Web of Science ®Google Scholar
• ROSENSON RS: Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc. Ther. (2003) 1(4):495–505.
   PubMedGoogle Scholar
• HUNNINGHAKE DB, STEIN EA, BAYS HE et al.: Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron. Artery Dis. (2004) 15(3):115–123.
   PubMedGoogle Scholar
• WOLFE SM: Dangers of rosuvastatin identified before and after FDA approval. Lancet (2004) 363(9427):2189–2190.
   PubMed Web of Science ®Google Scholar
• SIDAWAY JE, DAVIDSON RG, MCTAGGART F et al.: Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. Am. Soc. Nephrol (2004) 15(9):2258–2265.
   PubMed Web of Science ®Google Scholar
• VIDT DG, CRESSMAN MD, HARRIS S, PEARS JS, HUTCHINSON HG: Rosuvastatin-induced arrest in progression of renal disease. Cardiology (2004) 102(2):52–60.
   PubMedGoogle Scholar
• KAJINAMI K, TAKEKOSHI N, SAITO Y: Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev (2003) 21(3):199–215.
   PubMed Web of Science ®Google Scholar
• WAJIMA T, MAKITA S, OSHIMA K: Effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits and cholesterol-fed rabbits. Pharmacology (2004) 70(3):123–129.
   PubMed Web of Science ®Google Scholar
• WAJIMA T, MAKITA S, OSHIMA K: Direct vascular effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Clin. Exp. Pharmacol Physiol. (2003) 30(12):958–962.
   PubMed Web of Science ®Google Scholar
• ENDO A, TSUJITA Y, KURODA M, TANZAWA K: Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. Biochem. (1977) 77(1):31–36
   PubMedGoogle Scholar
• BROWN MS, GOLDSTEIN JL: A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 232(4746):34–47.
   PubMed Web of Science ®Google Scholar
• MARAIS AD, NAOUMOVA RP, FIRTH JC, PENNY C, NEUWIRTH CK, THOMPSON GR: Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. (1997) 38(10):2071–2078.
   PubMed Web of Science ®Google Scholar
• BROUSSEAU ME, SCHAEFER EJ, WOLFE ML et al: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl. I Med. (2004) 350(15):1505–1515.
   PubMed Web of Science ®Google Scholar
• •A new approach for the treatment of patients with low HDL levels.
   Google Scholar
• MIYAZAKI A, SAKAI M, SAKAMOTO Y, HORIUCHI S: Acyl-coenzyme A: cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis. Curr. Opin. Investig. Drugs (2003) 4(9):1095–1099.
   PubMedGoogle Scholar
• BORGHI C: Interactions between hypercholesterolemia and hypertension: implications for therapy. Curt: Opin. Nephrol. Hypertens. (2002) 11(5):489–496.
   PubMed Web of Science ®Google Scholar
• BORGHI C, DORMI A, VERONESI M, IMMORDINO V, AMBROSIONI E: Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. ./. Clin. Hypertens. (2002) 4(4):277–285.
   PubMedGoogle Scholar
• VAN DOKKUM RP, HENNING RH, DE ZEEUW D. Statins: cholesterol, blood pressure and beyond. J. Hypertens. (2002) 20(12):2351–2353.
   Google Scholar
• BROWN BG, ZHAO XQ: Importance of endothelial function in mediating the benefits of lipid-lowering therapy. Am. Cardiol (1998) 82(10B):49T–52T.
   Google Scholar
• LAUFS U, LA FATA V, PLUTZKY J, LIAO JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation (1998) 97(12):1129–1135.
   PubMed Web of Science ®Google Scholar
• WASSMANN S, LAUFS U, BAUMER AT et al.: Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Racl GTPase. Mol Pharmacol (2001) 59(3):646–654.
   PubMed Web of Science ®Google Scholar
• KIM SI, HAN DC, LEE HB: Lovastatin inhibits transforming growth factor-131 expression in diabetic rat glomeruli and cultured rat mesangial cells. J. Am. Soc. Nephrol (2000) 11(1):80–87.
   PubMed Web of Science ®Google Scholar
• ZOJA C, CORNA D, CAMOZZI D et al: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. I Am. Soc. Nephrol (2002) 13(12):2898–2908.
   PubMed Web of Science ®Google Scholar
• ZAMRINI E, MCGWIN G, ROSEMAN JM: Association between statin use and Alzheimer's disease. Neuroepidemiology (2004) 23(1-2):94–98.
   PubMed Web of Science ®Google Scholar
• STUVE 0, YOUSSEF S, STEINMAN L, ZAMVIL SS: Statins as potential therapeutic agents in neuroinflammatory disorders. Curt: Opin Neurol (2003) 16(3):393–401.
   PubMed Web of Science ®Google Scholar
• MUNDY G, GARRETT R, HARRIS S et al.: Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 286(5446):1946–1949.
   PubMed Web of Science ®Google Scholar
• GARRETT IR, MUNDY GR: The role of statins as potential targets for bone formation. Arthritis Res. (2002) 4(4):237–240.
   PubMedGoogle Scholar
• BAUER DC, MUNDY GR, JAMAL SA et al: Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch. Intern. Med. (2004) 164(2):146–152.
   PubMedGoogle Scholar
• LACROIX AZ, CAULEY JA, PETTINGER M et al: Stain use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann. Intern Med. (2003) 139(2):97–104.
   PubMed Web of Science ®Google Scholar
• PALINSKI W, TSIMIKAS S: Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. ./. Am. Soc. Nephrol (2002) 13(6):1673–1681.
   PubMed Web of Science ®Google Scholar
• KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6(12):1399–1402.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7(6):687–692.
   PubMed Web of Science ®Google Scholar
• CHAN KK, OZA AM, SIU LL. The statins as anticancer agents: Clin. Cancer Res. (2003) 9(1):10–19.
   PubMed Web of Science ®Google Scholar
• GRAAF MR, BEIDERBECK AB, EGBERTS AC, RICHEL DJ, GUCHELAAR HJ: The risk of cancer in users of statins. I Clin. Oncol (2004) 22(12):2388–2394.
   PubMed Web of Science ®Google Scholar
• POYNTER JN, RENNERT G, BONNER D, RENNERT HS, GREENSON JK, GRUBER SB: HMG-CoA reductase inhibitors and the risk of cancer. 40th American Socie0, of Clinical Oncology Meeting. New Orleans, USA (2004).
   Google Scholar
• BELL IM: Inhibitors of protein prenylation 2000. Expert Opin. Ther. Patents (2000) 10(19):1813–1831.
   Google Scholar
• KARAMOUZIS MV, PAPAVASSILIOU AG: COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet? Expert Opin. Investig. Drugs (2004) 13(4):359–372.
   Google Scholar
• BALLANTYNE CM, CORSINI A, DAVIDSON MH et al: Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. (2003) 163(5):553–564.
   PubMedGoogle Scholar
• •A comprehensive review on statin-related toxicity.
   Google Scholar
• STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl. I Med. (2002) 346(7):539–540.
   PubMed Web of Science ®Google Scholar
• SORELLE R Baycol withdrawn from market. Circulation (2001) 104(8):E9015–E9016.
   Google Scholar
• NO AUTHORS LISTED: OTC statins: a bad decision for public health. Lancet (2004) 363(9422):1659.
   PubMed Web of Science ®Google Scholar
• MOOSMANN B, BEHL C. Selenoprotein synthesis and side-effects of statins: Lancet (2004) 363(9412):892–994.
   PubMed Web of Science ®Google Scholar
• McKILLOP T: The statin wars. Lancet (2003) 362 (9394):1498.
   PubMed Web of Science ®Google Scholar
• MCKENNEY JM: Optimizing LDL-C lowering with statins. Am. .1 Ther. (2004) 11(1):54–55.
   Google Scholar